Commentary|Videos|March 16, 2026

Deescalation vs Intensification: How to Ensure Patients Get the Treatment They Need

Fact checked by: Paige Britt

MRD testing personalizes diffuse large B‑cell lymphoma therapy—shorten chemo for early responders and flag high‑risk patients for targeted add‑ons.

In an interview with Targeted Oncology, Hua-Jay “Jeff” Cherng, MD, assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology at the Columbia University Irving Medical Center, discussed how to ensure patients with lymphoma receive the proper level of treatment based on molecular response in clinical trials.


Related to this article

FDA Removes PCNSL Limitation From Liso-Cel Label
The November 2026 prescribing information removes the limitation that previously excluded patients with primary or secondary central nervous system lymphoma from the therapy’s large B-cell lymphoma indications.